Inflammatory Bowel Disease

PACE / State of CA / State of FL
In this month’s “Virtual Lecture,” Michael Camilleri, M.D., discusses the leaky gut, helping to understand components of the intestinal barrier, how to measure its permeability, review literature about effects that stress and diet have on permeability, and takes a futuristic look at barrier disfunction in the context of inflammatory bowel disease.

By MCL Education • October 21, 2021

Identification of early-onset IBD patients may enable tailored treatment and surveillance plans. With over 50 genes implicated in early-onset IBD, genetic testing should be included in the workup of children under the age of six with IBD. Join Mayo Clinic, in this “Specialty Testing” webinar, for a discussion of this testing and its clinical application.

By MCL Education • August 13, 2019

Ann Moyer, M.D., Ph.D., gives an overview of the inflammatory bowel disease primary immunodeficiency testing available through Mayo Clinic Laboratories. She discusses when this testing should be ordered, how this testing improves upon previous testing approaches, and what clinical action can be taken due to the results of this testing.

By Emily Linginfelter • February 5, 2019

Many patients may have flare-ups of their disease, or they may stop responding to treatment. In these situations, the clinician may choose to increase the dose administered or recommend more frequent injections. One cause of decreased response to treatment is the appearance of anti-drug antibodies or “immunogenicity.”

By Mayo Clinic Laboratories • September 7, 2018

This "Specialty Testing" webinar will outline the different tests to detect patients who are at risk for thiopurine-related toxicity and the advantages of each test.

By MCL Education • November 6, 2017

Ann Moyer, M.D., Ph.D., discusses an additional gene, NUDT15, which is important in the prediction of thiopurine-related toxicity This gene has been added to our TPMT genotyping assay available through Mayo Medical Laboratories.

By Mayo Clinic Laboratories • October 25, 2017

Detection of individuals with low thiopurine methyltransferase (TPMT) activity who are at risk for excessive myelosuppression or severe hematopoietic toxicity when taking thiopurine drugs.

By Mayo Clinic Laboratories • March 29, 2017

The differential diagnosis for inflammatory bowel disease (IBD) includes irritable bowel syndrome (IBS). While the clinical presentation is similar, IBD is an inflammatory disease, while IBS is a noninflammatory disease. View this "Hot Topic" to learn about testing for IBD and IBS.

By MCL Education • September 6, 2016